Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antigen-presenting cells (APCs) are immune cells that capture antigens from pathogens, process them, and present them on their cell surface to T lymphocytes. This interaction is essential for triggering specific adaptive immune responses. The process begins when APCs such as dendritic cells, macrophages, or B cells encounter pathogens. They internalize these pathogens through phagocytosis or other mechanisms and break them down into peptide fragments within intracellular compartments. These peptide fragments are then loaded onto major histocompatibility complex (MHC) molecules. There are two main pathways of antigen presentation: 1. MHC Class I Pathway: Presents endogenous antigens (from inside the cell, such as viral proteins) to CD8+ cytotoxic T cells. Almost all nucleated cells can present via this pathway. 2. MHC Class II Pathway: Presents exogenous antigens (from outside the cell) to CD4+ helper T cells. This pathway is primarily used by professional APCs. When a T cell encounters its specific antigen presented by an APC, along with appropriate co-stimulatory signals, it becomes activated. This activation leads to T cell proliferation and differentiation into effector cells that coordinate the immune response. Dendritic cells are considered the most potent APCs and play a crucial role in initiating primary immune responses. They capture antigens in peripheral tissues and migrate to lymphoid organs where they interact with naïve T cells. The APC-T cell interaction is highly specific and regulated. It involves not only the MHC-peptide complex binding to the T cell receptor but also co-stimulatory molecules that provide additional signals necessary for full T cell activation. This process is vital for immune tolerance as well. In the gut, for example, certain dendritic cell subsets (particularly cDC1s) present food antigens to T cells in a way that promotes the differentiation of regulatory T cells, preventing inappropriate immune responses to harmless food proteins. Disruptions in antigen presentation can lead to various pathologies, including autoimmune diseases, ineffective responses to infections, and cancer immune evasion. Understanding and potentially modulating this process has significant implications for developing immunotherapies and vaccines.
The mechanism of APC interaction involves several key steps: Antigen capture through phagocytosis, endocytosis, or other internalization methods; Antigen processing within endosomes/lysosomes (for MHC-II) or cytosol (for MHC-I); Loading of antigenic peptides onto MHC molecules; Transport of peptide-MHC complexes to the cell surface; Presentation of antigens to T cells via MHC-TCR interaction; Co-stimulatory signaling between APCs and T cells; T cell activation and differentiation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen-presenting cell interaction (APC interaction).